Year-end Sale % OFF 
Abstract
Praziquantel (PZQ) is a drug of choice for treating schistosomiasis mansoni. Praziquantel was effectively used to treat schistosomiasis, but there are reports that indicate the appearance of Praziquantel resistance. The objective of this study was to determine the rate of S. mansoni infection before and after single treatment, thus to measure the efficacy of Praziquantel in treating Schistosoma mansoni infected individuals in the study area. The study utilized microscopic examination of two Kato–Katz slides for each individual sample before and after treatment. The cure rate of S. mansoni infection by Praziquantel in the two study areas remains high and with no significant difference. In Timuga cure rate was 93.44% and in Waja 88.99% (?2= 3.644 and P= 0.16). Efficacy of Praziquantel in treating infections due to S. mansoni is still high and there is no evidence for resistance S. mansoni against Praziquantel in Tumuga and Waja. Key words: Efficacy, Praziquantel, Schistosomiasis, School children.
Highlights
Schistosomiasis is responsible for 500,000 deaths annually (Dupre et al, 1999)
When compared with previous studies in Tumuga (Author, 2009), the prevalence of S. mansoni infection was 87%, in this report the infection reduces by 27.7% (Tadesse and Beyene, 2009)
The results of the present study indicated that there is no sex difference in S. mansoni infection in both pre- and post-treatment tests
Summary
Schistosomiasis is responsible for 500,000 deaths annually (Dupre et al, 1999). As reduction of schistosomiasis is still beyond human and financial resources, the aim of most control programs remains the reduction of morbidity by treating infected people on an individual or population basis by using chemotherapy agents such as Praziquantel (WHO, 1993). Praziquantel was effectively used to treat schistosomiasis since the last two decades (WHO, 1993; Magnussen, 2003). As the drug is supplied by a reasonable price in hospitals, still in Ethiopia, especially in the study area, Praziquantel is the drug of choice in treating schistosome infected individuals. Praziquantel is a drug of choice for treating schistosomiasis mansoni (Day et al, 1992, Redman et al, 1995). It has been reported that Praziquantel has shown a remarkable impact in reducing morbidity due to schistosomiasis (WHO, 2000).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
